Key result
Renin angiotensin aldosterone system (RAAS) inhibition is associated with reduced rates of cognitive and functional decline in mild cognitive impairment and dementia based on observational evidence.
Why the study?
Does RAAS inhibition reduce cognitive and functional decline in patients with mild cognitive impairment and dementia?
Population
Patients with mild cognitive impairment (MCI) and dementia
Design
Review
Authors
Loading...
Should not yet change practice in MCI or dementia; leaves open benefit of RAAS inhibition pending RCTs.
Does RAAS inhibition reduce cognitive and functional decline in patients with mild cognitive impairment and dementia?
RAAS inhibitors may offer a therapeutic strategy to reduce cognitive decline in dementia and MCI, highlighting the need for dedicated randomized controlled trials.
Ó’Caoimh et al. (2014) conducted a review in Dementia and mild cognitive impairment (MCI). Renin angiotensin aldosterone system (RAAS) inhibition was evaluated. Renin angiotensin aldosterone system (RAAS) inhibition is associated with reduced rates of cognitive and functional decline in mild cognitive impairment and dementia based on observational evidence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: